table spotlighting MAPK pathway inhibitors in optic pathway glioma (OPG) treatment. Fueled by frequent BRAF alterations, it details 
therapies like selumetinib, tovorafenib, and dabrafenib plus trametinib, 
packing trial data on efficacy, safety, and patient outcomesâ€”a musthave for clinicians and researchers.
The table serves as a valuable tool for understanding the current 
landscape of targeted therapies in OPGs, particularly in the context of 
delaying or avoiding more toxic treatments like radiation or alkylating